Purpose To determine the sites of first distant relapse in patients with or without pCR following neoadjuvant chemotherapy in breast cancer patients enrolled in the EORTC 10994/BIG-1-00 trial. Methods We included patients enrolled in the EORTC 10994/BIG-1-00 trial who received at least one chemotherapy cycle before surgery and who had been diagnosed with a distant relapse. pCR was defined as no evidence of residual invasive cancer in the primary tumor and axillary lymph nodes with or without residual ductal carcinoma in situ. Site of first distant relapse was categorized as 'soft tissue,' 'visceral,' 'skeletal,' 'central nervous system (CNS),' and 'other.' The association between relapse site and achievement of pCR was assessed using multivariate logistic regression models for molecular subtypes classification and preceding locoregional recurrence. Results The study included 383 (21%) eligible patients out of the 1856 randomized, of whom 28 (7%) had achieved pCR. Median follow-up was 5.4 years. Achievement of pCR was associated with a trend towards a decreased presentation of skeletal metastases [21% (pCR) vs. 50% (non-pCR), OR 0.32, adjusted p value = 0.071] and an increase in the proportion of patients with CNS metastases as first distant relapse site (21% vs. 9%, OR 2.39, adjusted p value = 0.183). Patients with pCR were more likely to present with only one relapse location category when compared to non-pCR (86% vs. 69%). Conclusion Patients that achieved a pCR appeared less likely to present with skeletal metastases and more frequently presented with CNS metastases as first site of distant relapse, even after adjustment for molecular subtypes.
Introduction
Neoadjuvant systemic therapy is a well-established strategy for locally advanced disease with the aim of downstaging the tumor to enable more conservative surgery. Additionally, over the last few years, it is also increasingly applied in early-stage breast cancer patients requiring systemic treatment showing similar long-term outcome as compared to adjuvant administration [1] [2] [3] [4] . The early administration of systemic therapy also permits 'in vivo' monitoring of the efficacy of administered systemic treatment [5] .
The achievement of a pathologic complete response (pCR) after neoadjuvant treatment is associated with improved longterm survival and a decrease in both locoregional and distant metastases [5] . The pCR rate varies according to molecular subtype as does the association between pCR and long-term outcomes, with the strongest correlation for the more aggressive subtypes [5] [6] [7] .
The widely accepted explanation for this association is that the biology of the primary tumor and the micrometastatic disease are similar, and respond equally to the systemic neoadjuvant therapy. However, at least 10% of patients whose tumor achieved a pCR develop a recurrence within 5 years and more than two-thirds of patients whose tumor did not achieve a pCR will not relapse [5] . In patients with triple-negative tumors, in whom neither adjuvant hormonal nor trastuzumab therapies are going to interfere with the association between pCR and outcome, 15-20% of patients whose tumor achieved a pCR develop a recurrence within 5 years and 50% of patients whose tumor did not achieve a pCR will not relapse [5, 6, 8] . Thus, although pCR is a good prognosticator for survival it is not perfect. Several series have reported differences in estrogen receptor (ER) or human epidermal growth receptor 2 (HER2) status between the primary tumor and distant metastases in up to 32 and 14.5%, respectively [9, 10] . The biology of the micrometastatic disease in distant sites is certainly more complex than the biology of the primary tumor [11] . One could hypothesize that the correlation between pCR and survival is excellent in some specific sites while it remains poor in other sites. The first obvious example would be central nervous system metastasis. To our knowledge, this question has never been addressed.
The aim of this study was to evaluate whether the sites of first distant relapse differed between patients whose tumor achieved a pCR after neoadjuvant chemotherapy versus those who did not in the EORTC 10994/BIG-1-00 trial [12] .
Methods

Study design, eligibility, and treatment
The EORTC 10994/BIG 1-00 trial enrolled patients aged ≤ 70 years with large operable or locally advanced/ inflammatory breast cancer without evidence of distant metastases, who were candidates for neoadjuvant treatment. Patients were randomly assigned to receive either six cycles of anthracycline-based chemotherapy (FEC), or a taxane-based regimen, docetaxel for three cycles followed by epirubicin + docetaxel for three cycles (T-ET), all given prior to primary surgery. Subsequent locoregional treatment was determined according to guidelines described in the study protocol. Women with hormone receptor-positive tumors were recommended to receive adjuvant endocrine therapy for 5 years. Patients with HER2-positive tumors were allowed to enter adjuvant clinical trials assessing trastuzumab or to receive this treatment in the adjuvant setting when it became standard practice [12] .
For this substudy, we selected a subgroup of patients based on the following criteria: (i) Patients eligible in the EORTC 10994/BIG 1-00 trial, (ii) patients who received at least one cycle of neoadjuvant chemotherapy and who underwent surgery, (iii) patients who had a known pathological response status, and (iv) patients diagnosed with a distant relapse after surgery of which the site was specified. Patients with T4d tumors or who received radiotherapy before surgery were excluded from the analysis.
Pathologic complete response was defined in this substudy as no evidence of residual invasive cancer (or very few scattered tumor cells) in the primary tumor and axillary lymph nodes with or without residual ductal carcinoma in situ (DCIS). Information on Ki-67 was not collected within the main study. Therefore, tumor subtype classification was performed according to the simplified approach as proposed in the 2011 St. Gallen consensus, where Ki-67 is replaced by tumor grade [13] (Supplement A). Tumor histology, grade, ER, progesterone receptor (PgR), and HER2 status were based on local pathology assessment of the diagnostic biopsy.
Objectives and end-points
The primary objective of this study was to assess whether there are differences in the sites of first distant relapse between patients who achieved a pCR after neoadjuvant chemotherapy versus those who did not (non-pCR). Secondary objectives included (1) describing the differences in site of first distant relapse in the pCR and nonpCR groups by breast cancer subtype, (2) describing the clinicopathological characteristics of patients according to site of first distant relapse, (3) evaluating the effect of a preceding or concomitant locoregional recurrence (LR) on the occurrence of a specific site as first distant relapse, (4) studying the association between concomitant sites of first distant relapse.
We evaluated the first site of distant relapse as reported in the case report forms, i.e., 'soft tissue,' 'visceral,' 'skeletal,' 'CNS,' or 'other.' In case of multiple lesions, all concomitant lesions at first presentation were included. As part of the secondary objectives, invasive locoregional recurrences were considered if they occurred before or at the same time of the first distant relapse. Locoregional recurrences were ipsilateral invasive breast recurrences and regional recurrences (chest wall and regional lymph nodes: axillary, internal mammary, infra, and supraclavicular).
Statistical analysis
A statistical analysis plan was prospectively developed. The association between the occurrence of a specific site of first distant relapse and pCR status was evaluated using four multivariate logistic regression models, one for each site ('soft tissue,' 'visceral,' 'skeletal,' 'CNS') except 'other,' adjusting for intrinsic subtype and preceding locoregional recurrence (yes/no). Sites of first distant relapse classified as 'other' were not evaluated because the obtained estimation would have not been interpretable due to the heterogeneity of the corresponding sites. The association with pCR was assessed using the Wald Chi-square test with adjusted p values for multiple testing (Benjamini-Hochberg correction). A p value < 0.05 was considered statistically significant. Sensitivity analyses were subsequently performed, with univariate and multivariate models adjusting for age, clinical tumor and nodal status, histologic tumor type, subtype, and allocated chemotherapy regimen. Differences in site of first distant relapse between the molecular subtypes according to pCRstatus, patient and tumor characteristics, and the presence of preceding locoregional recurrence per relapse site, and the occurrence of concomitant sites of first distant relapse were tabulated (no formal statistical testing was done due to the limited number of patients in the subgroups).
All statistical analyses were performed using SAS software version 9.4 (SAS Institute).
Results
Of the 1856 patients randomized in the trial, 383 patients diagnosed with a distant relapse were eligible for this substudy, of whom 28 (7%) were in the pCR-group and 355 (93%) in the non-pCR group. Reasons for ineligibility are shown in the consort diagram (Supplement B). The median follow-up was 5.4 years from date of randomization. Baseline patient and tumor characteristics according to pCR status are presented in Table 1 . Median age of included patients was 49 years and most patients had clinically node-positive disease (271/383; 71%). Overall, visceral (197/383; 51%) and skeletal metastases (185/383; 48%) were the most common sites of first distant relapse (Table 2) .
Association between pCR status and site of first distant relapse
Patients whose tumor achieved pCR were less likely to present with skeletal metastases as compared to non-pCR patients (6/28 (21%) versus 179/355 (50%) patients; OR 0.32, 95% CI 0.12-0.82; p = 0.071, Table 2 ). A similar trend was observed in all subtypes apart from Luminal A-like, though the numbers are very small (Table 3) .
Conversely, the proportion of patients with CNS metastasis as first metastatic site was numerically higher in the pCR-group as compared to in the non-pCR group (6/28 (21%) versus 32/355 (9%) patients; OR 2.39, 95% CI 0.87-6.58; p = 0.183, Table 2 ). This difference was greatest in the HER2 + Luminal B-like subtype (Table 3 ). These differences in the incidence of skeletal and CNS metastases between patients whose tumor did or did not achieve pCR remained after further adjustment for age, histologic type, clinical node and tumor status, subtype, and received chemotherapy regimen (data not shown).
For the remaining sites (soft tissue and visceral), we did not observe an association with pCR status (Tables 2).
Clinicopathological characteristics of patients according to site of first distant relapse
Patients with soft tissue and CNS metastases were older and had higher grade tumors as compared to patients with visceral and skeletal metastases (Table 4) . Patients presenting with skeletal metastasis more frequently had tumors with a lobular histology, a lower-grade (I and II), and a luminal-like subtype (17, 54, and 59%, respectively). Patients presenting with CNS metastases were predominantly clinically node positive (84% N + vs. 16% N0, Table 4 ). Furthermore, in these patients, we observed a higher rate of HER2 +/nonluminal and TN breast cancer.
Preceding locoregional recurrence
In 68 patients, the first distant relapse was preceded by or occurred concomitantly with a locoregional recurrence ( Table 1) . The proportion of patients with a prior LR was highest in those presenting with soft tissue metastases [18/47 (38%) versus 13% (CNS) to 19% (visceral) in the other groups (Table 4) ]. We did not observe differences in site of Percentages may not add up to 100% due to rounding 
Association between pCR status and extent of metastatic disease
The proportion of patients who presented with more than one site of metastatic spread was numerically lower in the group of patients whose tumor achieved a pCR as compared to patients in the non-pCR group (4/28 (14%) versus 112/355 (32%) patients with > 1 relapse site, Table 5 ).
Patients with soft tissue as first site of distant relapse most frequently presented with at least one other metastatic site [32/47 patients (68%)]. In 60% of patients with CNS as first site of distant relapse, the CNS was the only site of metastatic disease. Skeletal and visceral metastases were the most common combination in case of more than one site of relapse [70 out of 116 patients (60%) with > 1 metastatic site, Table 5 ]. 
Discussion
In this study, there was a numerical difference in presentation with CNS metastasis, with a higher incidence in the pCR group (Odds Ratio 2.39). Of note, CNS metastasis accounted for one-fifth of all first distant metastasis in the pCR group. This finding supports the concept of the brain being a sanctuary site where malignant cells are protected from anti-cancer therapeutics by the blood-brain barrier [14] . Patients with a non-luminal HER2 + or TN subtype have higher pCR rates as compared to patient with luminal subtypes [5] and have been shown to more frequently metastasize to the brain and viscera [15, 16] . Thus, an excess of CNS metastases in the pCR group might be expected in the non-luminal HER2 + and TN subtypes.
Furthermore, patients whose tumor achieved a pCR had a lower rate of skeletal metastasis as first site of distant relapse as compared to patients whose tumor did not achieve pCR (Odds Ratio 0.32). This observed difference could perhaps have been explained by a molecular subtype bias. Patients with a luminal subtype are less likely to achieve a pCR and are known to more frequently metastasize to skeletal tissue [17, 18] .
We also evaluated the influence of a preceding LR, since such an event could have an influence on the subsequent distant metastatic spread as these patients might receive additional systemic treatment. Furthermore, the local recurrence itself could give rise to metastatic spread. We did not observe a statistically significant association between a prior LR and any site of first distant relapse after adjustment for pCR status and subtype. These results should be interpreted with caution since the number of LRs preceding distant relapses was relatively low.
The median follow-up of patients included in this study was 5.4 years. This time frame will have an influence on the distribution of relapse sites we observed. Previous studies have shown that patients with a shorter diseasefree survival (DFS) more often present with visceral and CNS metastases [19] . The incidence of these metastatic sites reaches its peak in the second year of follow-up after which the incidence declines, whereas bone metastases can even occur later on. Furthermore, patients with a shorter DFS are more often of the TN subtype which is known to metastasize frequently to the visceral tissue as is also demonstrated in this study [8, 20, 21] . Longer follow-up is needed.
This study has strengths and limitations. A major strength of the study is that the population consists of patients from a large randomized trial with a total of 383 patients with events of interest. The main limitation is the small number of patients in the pCR group, which prohibits drawing firm conclusions from this study. This limitation is even more important when trying to analyze the results by molecular subtypes. It is well known that the metastatic behavior and prognosis of breast cancer are dependent on tumor biology of the different intrinsic subtypes [22] . We attempted to adjust for possible molecular subtype bias by performing multivariate analyses.
In conclusion, there appear to be differences in the occurrence of tissue-specific sites of first distant relapse between patients that achieved pCR after neoadjuvant chemotherapy when compared to those that did not, even after adjustment for molecular subtypes. The trends observed in the present study need to be confirmed in a meta-analysis as well to establish the clinical implication on long-term prognosis.
